Pacific Edge Investor Relations Material

Pacific Edge Limited is a New Zealand-based biotechnology company specializing in the development of diagnostic tools for cancer detection and management. The company’s primary focus is on non-invasive diagnostic tests for urological cancers, particularly bladder cancer. Pacific Edge’s tests utilize molecular technology to aid in early cancer detection, monitoring, and management, providing alternative solutions to traditional diagnostic methods. These tools are designed for use in clinical and laboratory settings. The company is headquartered in Dunedin, New Zealand, and its shares are listed on the NZX.